ArticleOncotarget2018
Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Preclinical Study of Radiolabeled LyP-1 for Detecting Sunitinib-induced Changes in the Tumor Microenvironment and Synergistic Antitumor Effects in Triple-negative Breast Cancer.Molecular imaging and biology · 2026Article
- LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting.ACS pharmacology & translational science · 2025Article
- Effects of LinTT1-peptide conjugation on the properties of poly(ethylene glycol)-block-(ε-caprolactone) nanoparticles prepared by the nanoprecipitation method.Drug delivery and translational research · 2025Article
- Advancing Cancer-Targeted Nanotherapies with Tumor Homing Peptides.ACS pharmacology & translational science · 2025Review
- Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.Scientific reports · 2024Article
- Targeting of Tomato Bushy Stunt Virus with a Genetically Fused C-End Rule Peptide.Nanomaterials (Basel, Switzerland) · 2023Article
- Recent advances in peptide-based therapeutic strategies for breast cancer treatment.Frontiers in pharmacology · 2023Review
- Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.ACS applied materials & interfaces · 2022Article
- CoreNanoscale advances · 2022Article
- Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis.Nanomaterials (Basel, Switzerland) · 2021Article
- Paper-based lateral flow assay using rhodamine B-loaded polymersomes for the colorimetric determination of synthetic cannabinoids in saliva.Mikrochimica acta · 2021Article
- Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma.Pharmaceutics · 2021Article
- Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics.Pharmaceutics · 2021Review
- Novel Anthracycline Utorubicin for Cancer Therapy.Angewandte Chemie (International ed. in English) · 2021Article
- Novel Anthracycline Utorubicin for Cancer Therapy.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2021Article
- The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.Cancers · 2021Review
- Pro-Tumorigenic Macrophage Infiltration in Oral Squamous Cell Carcinoma and Possible Macrophage-Aimed Therapeutic Interventions.Frontiers in oncology · 2021Review
- Targeting Tumors Using Peptides.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 5 countries.
Funding
Abstract
Triple negative breast cancer (TNBC) is the deadliest form of breast cancer and its successful treatment critically depends on early diagnosis and therapy. The multi-compartment protein p32 is overexpressed and present at cell surfaces in a variety of tumors, including TNBC, specifically in the malignant cells and endothelial cells, and in macrophages localized in hypoxic areas of the tumor. Herein we used polyethylene glycol-polycaprolactone polymersomes that were affinity targeted with the p32-binding tumor penetrating peptide LinTT1 (AKRGARSTA) for imaging of TNBC lesions. A tyrosine residue was added to the peptide to allow for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.